Project Grant R43GM140499

Award Date 2/1/21
Completion Date 7/31/23
Dollars Obligated $732K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $205,926 to Abbratech Inc., a small disadvantaged biotechnology business located in Branford, CT. The overarching goal of this "Fast Track" research project is to develop a comprehensive platform for identifying and validating recombinant antibodies that target protein isoform splice-junction sites. This addresses key...
This $667,013 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop machine learning models to predict antigen-antibody interactions from high-throughput sequencing data. The key objectives are to: Develop and validate deep learning models to accurately identify antibody-antigen interactions and binding epitopes from massive sequencing data (Aim 1). Integrate B cell...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $303,024 to Biocognon LLC to develop an innovative combinatorial nanobody discovery platform for G-protein coupled receptors (GPCRs). The project aims to: Develop a robust assembly system for creating GPCR/nanobody libraries, Build a synthetic nanobody library targeting the ADRB1 and ADRB2 GPCRs and validate therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,000,000 in funding to Partillion Bioscience Corp. to develop advanced workflows that utilize their specialized "nanovial" hydrogel microparticle technology. The goal is to enable ultra high-throughput screening and functional assessment of single B cells and antibody-secreting cells to improve antibody...
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This federal Project Grant award of $342,776 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop foundational data science methods and a pipeline for efficient and exceptional monoclonal antibody (mAb) formulation. The key objectives of this 4-year project are to: 1) prototype experimental and data handling methodologies, 2) perform a...
This $2 million cooperative agreement from the National Science Foundation will support Protabit LLC in developing artificial intelligence-enabled antibody engineering approaches to generate neutralizing antibodies against SARS-CoV-2. Funded through Jul 2022 to Jun 2024 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the project aims to discover a large array of high-affinity neutralizing antibodies targeting multiple regions of the SARS-CoV-2 spike protein. This...
This SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $274,932 to Femtofluidics Incorporated to develop hardware that can rapidly and inexpensively synthesize DNA-encoded libraries (DELs) for accelerating drug discovery. The project aims to build a device that can perform combinatorial chemistry on nanoliter to picoliter droplets using an electronic substrate, without any moving or mechanical parts. This...
This Project Grant award of $350,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop an artificial intelligence-based platform for optimizing peptide-based drug candidates. The key products or services to be delivered include: Methods for encoding non-canonical amino acids and cyclic peptides to enable high-performance machine learning on commercial peptide sequence, activity, stability, and...

INTELLIGENT IN SILICO ANTIBODY LIBRARY DESIGN AND OPTIMIZATION FOR THERAPEUTIC USE - ANTIBODY DISCOVERY TECHNOLOGIES HAVE DELIVERED LIFE SAVING THERAPIES OVER THE PAST THREE DECADES, HOWEVER, MANY CHALLENGING TARGETS REMAIN UNDRUGGED DUE TO LIMITATIONS OF THESE TECHNOLOGIES. PHAGE DISPLAY TECHNOLOGY PRESENTS A SOLUTION TO DISCOVERING ANTIBODIES TO TARGETS THAT DO NOT ELICIT A STRONG IMMUNE RESPONSE IN ANIMALS, ARE TOXIC, OR ARE DIFFICULT TO PRODUCE IN LARGE QUANTITIES IN THE CORRECT CONFORMATION. SYNTHETIC LIBRARIES, IN WHICH ANTIBODIES ARE DESIGNED IN SILICO, ARE A PROMISING APPROACH THAT DOES NOT RELY ON ANIMAL IMMUNIZATIONS OR DONORS. HOWEVER, MOST SYNTHETIC LIBRARIES IN USE TODAY WERE CONSTRUCTED BY FIXING CERTAIN REGIONS OF THE ANTIBODY WHILE GENERATING RANDOM SEQUENCES FROM POSITION-SPECIFIC AMINO ACID FREQUENCIES FOR ANTIGEN-BINDING REGIONS. THIS DEPARTURE FROM THE SPACE OF NATURAL ANTIBODIES RESULTS IN ANTIBODIES WITH POOR BIOPHYSICAL CHARACTERISTICS SUCH AS LOW MELTING TEMPERATURE, AGGREGATION PROPENSITY, OR GENERAL 'STICKINESS'. DIGITAL PROTEOMICS HAS DEVELOPED A COMPUTATIONAL WORKFLOW FOR NATURAL ANTIBODY REPERTOIRE ANALYSIS, HARNESSING THE THROUGHPUT OF NEXT-GENERATION SEQUENCING OF IMMUNE CELLS, THAT WILL BE USED TO DESIGN A BETTER SYNTHETIC LIBRARY FOR THERAPEUTIC ANTIBODY DISCOVERY. RULES OF NATURAL ANTIBODY DEVELOPMENT WILL BE INCORPORATED INTO THE DESIGN OF A SYNTHETIC ANTIBODY LIBRARY, THEREBY RETAINING THE BIOPHYSICAL PROPERTY PROFILE OF NATURAL ANTIBODIES. ANTIBODY GENES DEVELOP THROUGH A SEQUENTIAL PROCESS INVOLVING SITE-SPECIFIC GENOME RECOMBINATION AND SOMATIC HYPERMUTATION, WHICH WILL BE MODELED IN SILICO. WHILE IN CONVENTIONAL ANTIBODIES, THIS PROCESS OCCURS AT TWO INDEPENDENT LOCI (A HEAVY AND LIGHT CHAIN THAT MUST INTERACT), THE PROOF-OF-CONCEPT WILL BE APPLIED TO THE SINGLE CHAIN ANTIBODIES PRODUCED BY CAMELIDS. USING AN IMPROVED SYNTHETIC LIBRARY FRAMEWORK, THE COMPUTATIONAL DESIGN OF AN ANTIBODY LIBRARY OPTIMIZED FOR THERAPEUTIC DISCOVERY WILL CONTAIN ANTIBODIES THAT DISPLAY SUPERIOR BIOPHYSICAL PROPERTIES AND REDUCED SEQUENCE LIABILITIES. THE LIBRARY WILL BE AN INVALUABLE TOOL FOR RAPID DISCOVERY OF THERAPEUTIC ANTIBODIES TO A WIDE RANGE OF DISEASES.

Posted 1/25/21, 12:00 AM